Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced that on December 17, its U.S. subsidiary, Eisai Medical Research Inc. (Headquarters: New Jersey, President: Mindell Seidlin), submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for two new formulations of ARICEPT , a rapid disintegration tablet and a liquid formulation.
The new forms of ARICEPT is designed to make administration easier for patients who have difficulty swallowing tablets and will contribute to improved compliance for patients suffering from Alzheimer's disease. Eisai submitted an NDA for a rapid disintegration tablet in Japan in March 2003.
ARICEPT , an acetylcholinesterase inhibitor developed by Eisai Co., Ltd. in Japan, increases the concentration of acetylcholine, a neurotransmitter in the brain. ARICEPT is currently indicated for the treatment of mild to moderate Alzheimer's disease and is marketed in 62 countries worldwide. Eisai markets ARICEPT through copromotion with Pfizer in Japan, the United States, the United Kingdom, Germany, France and Spain, and markets solely in Asian countries.
Eisai Co., Ltd.
Public Relations Department
Phone 03-3817-5120 (Tokyo)